Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Eyeing Biotech's Newest Darling

"Management thinks Eylea can bring in $140 million to $160 million in sales this year, although I'd guess that's a conservative estimate and they're hoping for more."
-- Me

Oh, what a difference a month makes.

Regeneron Pharmaceuticals (Nasdaq: REGN  ) upped its sales guidance for the age-related macular degeneration treatment to $250 million to $300 million this year. At the top, that's a doubling of expected revenue.

"This year's sales aren't enough to justify Regeneron's $7 billion market cap on their own." 

Yup, me again.

Regneneron's market cap is up to $10.5 billion now. That's great for investors that have held shares over the last month. And it's not too surprising considering the recent lackluster launches of Dendreon's (Nasdaq: DNDN  ) Provenge and Benlysta from Human Genome Sciences (Nasdaq: HGSI  ) and GlaxoSmithKline (NYSE: GSK  ) . It's easier to become biotech's new darling with the bar set lower by Provenge and Benlysta.

But Regeneron has entered the be-careful valuation range. A price to sales ratio of 35 at the high end of guidance is a bit pricey. Technically, it's come down from the 43-plus when the original guidance was released, but as I said last month, that looked pretty conservative.

Of course, the ultimate valuation -- and therefore the ultimate returns for long-term investors -- won't be based on the sales this year or even the ramp up over the next few years, but rather the peak sales that Eylea and its pipeline can achieve. I'm not convinced Regeneron deserves the nearly 50% increase it has experienced over the last month because I'm not convinced the new sales info really changes the peak sales potential.

Sales guidance could double again next month, but I wouldn't count on it. I've made an underperform CAPScall on the stock. It's not a knock on Eylea or the rest of the pipeline, but I think there's probably better places to put your money while Regeneron grows into its new, larger britches.

Fool analysts think they've found another health-care company with just as much growth potential as Regeneron. You can read about it in their new free report: "Discover the Next Rule-Breaking Multibagger." Get your copy for free by clicking here.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Dendreon. Motley Fool newsletter services have recommended buying shares of GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (1) | Recommend This Article (8)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1779841, ~/Articles/ArticleHandler.aspx, 10/28/2016 10:37:29 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,193.34 23.66 0.13%
S&P 500 2,134.51 1.47 0.07%
NASD 5,212.56 -3.41 -0.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/28/2016 10:21 AM
REGN $353.04 Down -12.31 -3.37%
Regeneron Pharmace… CAPS Rating: ****
DNDNQ $0.00 Down +0.00 +0.00%
Dendreon Corp CAPS Rating: *
GSK $40.21 Down -0.22 -0.53%
GlaxoSmithKline CAPS Rating: ***
HGSI.DL $0.00 Down +0.00 +0.00%
Human Genome Scien… CAPS Rating: **